SCHEMBL9824820

SCHEMBL9824820

O=Cc1cc([N+](=O)[O-])ccc1OCCBr

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.52
ALDH1A1 P00352 5/20 0.52
ERN1 O75460 2/20 0.51
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
CYP2D6 P10635 2/20 0.43
MAPK1 P28482 1/20 0.43
HPGD P15428 3/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA9 Q16790 1/20 0.41
S1PR4 O95977 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7400011 0.91 MAPT (0.50) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL28418478 0.90 ALDH1A1 (0.55) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL215546 0.85 CYP19A1 (0.54) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL824063 0.85 MAPT (0.52) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL7367561 0.84 ALDH1A1 (0.55) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL28825735 0.84 MAPT (0.55) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL31327257 0.84 MAPT (0.55) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL9825468 0.84 MAPT (0.51) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL8164842 0.83 ERN1 (0.53) MAPTALDH1A1ERN1LMNASMN1; SMN2
SCHEMBL4998777 0.83 MAPT (0.56) MAPTALDH1A1ERN1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404241-B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith CELGENE CORPORATION (US) 2025-09-02 US disclosed
CN-119219606-A Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same 细胞基因公司 2024-12-31 CN disclosed
US-20240368083-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORP (US) 2024-11-07 US disclosed
CN-113453681-B Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same 细胞基因公司 2024-10-11 CN disclosed
US-11873283-B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith CELGENE CORPORATION (US) 2024-01-16 US disclosed
US-20230002321-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORP (US) 2023-01-05 US disclosed
EP-3897636-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Celgene Corporation (US) 2021-10-27 EP disclosed
US-11149007-B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith CELGENE CORPORATION (US) 2021-10-19 US disclosed
CN-113453681-A Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same 细胞基因公司 2021-09-28 CN disclosed
WO-2020132014-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORPORATION (US) 2020-06-25 WO disclosed
US-20200199073-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2020-06-25 US disclosed
EP-0167371-B1 DIHYDROPYRIDINE COMPOUNDS, THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-03-06 EP disclosed
US-4727082-A CARDIOVASCULAR DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1988-02-23 US disclosed
EP-0167371-A2 Dihydropyridine compounds, their production, and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1986-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002321-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH AR, NR5A2, ESRRA MAPT 3086/4885ALDH1A1 442/4885ERN1 3556/4885
US-11873283-B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith AR, NR5A2, ESRRA MAPT 3086/4885ALDH1A1 442/4885ERN1 3556/4885
US-20240368083-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH AR, NR5A2, ESRRA MAPT 3086/4885ALDH1A1 442/4885ERN1 3556/4885
US-11149007-B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith AR, NR5A2, ESRRA MAPT 3086/4885ALDH1A1 442/4885ERN1 3556/4885
US-20200199073-A1 SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH AR, NR5A2, ESRRA MAPT 3086/4885ALDH1A1 442/4885ERN1 3556/4885
US-12404241-B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith AR, NR5A2, ESRRA MAPT 3086/4885ALDH1A1 442/4885ERN1 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.